LONDON - The UK regulator uncovered some discrepancies with Good Clinical Practice in its investigation into the Phase I safety trial of TeGenero AG's TGN1412, but stuck to the original conclusion that the life-threatening cytokine storm suffered by six health volunteers was due to "an unexpected biological effect." (BioWorld International)